Arbutus Biopharma Corp: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 5, 2020 and accepted by EDGAR at Nov 5, 2020, 16:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $1.5m | us-gaap:Revenues |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $4.5m | us-gaap:Revenues |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $12.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $32.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$15.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$41.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $1.1m | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $3.2m | us-gaap:InterestExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$18.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$46.7m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$36.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $77.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $96.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $121.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $131.1m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $7.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $33.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-09-30 | $97.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001447028-20-000150. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.